CSBR · CIK 0000771856 · operating
Champions Oncology is a technology-enabled research company providing services and software solutions for oncology drug discovery and development. The company operates its Tumorgraft technology platform, which involves implanting human tumors into immune-deficient mice to enable personalized cancer research and facilitate preclinical drug testing. This approach allows pharmaceutical and biotechnology companies to evaluate therapeutic candidates in tumor models that retain human genetic characteristics.
The company generates revenue through translational oncology research services leveraging its Tumorgraft platform, supporting clients throughout the drug development process. It also offers Lumin Bioinformatics, an oncology-focused software platform containing data derived from its research services and clinical studies to support decision-making in drug development. The company markets these offerings directly to pharmaceutical and biotechnology companies through its sales force and digital channels.
Based in Hackensack, New Jersey, Champions Oncology operates with approximately 213 full-time employees and maintains a primarily U.S.-focused business model. The company was incorporated in 1985 and changed its name from Champions Biotechnology to Champions Oncology in 2011 to reflect its specialized focus on cancer research applications.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $0.33 | $0.34 | +161.1% | |
| 2024 | $-0.54 | $-0.54 | -38.5% | |
| 2023 | $-0.39 | $-0.39 | -1075.0% | |
| 2022 | $0.04 | $0.04 | +100.0% | |
| 2021 | $0.02 | $0.03 | +111.8% | |
| 2020 | $-0.17 | $-0.17 | -1800.0% | |
| 2019 | $0.01 | $0.01 | — | |
| 2018 | — | — | — | |
| 2017 | — | — | — | |
| 2016 | $-1.20 | $-1.20 | -566.7% | |
| 2015 | $-0.18 | $-0.18 | — | |
| 2014 | — | — | — | |
| 2013 | — | — | — | |
| 2012 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-04-30 | 2025-07-23 | 0001628280-25-035765 | SEC ↗ |
| 2024-04-30 | 2024-07-19 | 0001628280-24-032321 | SEC ↗ |
| 2023-04-30 | 2023-07-24 | 0001628280-23-025464 | SEC ↗ |
| 2022-04-30 | 2022-07-22 | 0001628280-22-019309 | SEC ↗ |
| 2021-04-30 | 2021-07-26 | 0001628280-21-014464 | SEC ↗ |
| 2020-04-30 | 2020-07-28 | 0001628280-20-010734 | SEC ↗ |
| 2019-04-30 | 2019-07-29 | 0001628280-19-009139 | SEC ↗ |
| 2018-04-30 | 2018-07-30 | 0001628280-18-009773 | SEC ↗ |
| 2017-04-30 | 2017-07-28 | 0001628280-17-007429 | SEC ↗ |
| 2016-04-30 | 2016-07-29 | 0001628280-16-017936 | SEC ↗ |
| 2015-04-30 | 2015-07-29 | 0001144204-15-044834 | SEC ↗ |
| 2014-04-30 | 2014-07-28 | 0001144204-14-045199 | SEC ↗ |
| 2013-04-30 | 2013-07-26 | 0001144204-13-041406 | SEC ↗ |
| 2012-04-30 | 2012-07-18 | 0001144204-12-040031 | SEC ↗ |
| 2011-04-30 | 2011-07-15 | 0001144204-11-040755 | SEC ↗ |
| 2010-04-30 | 2010-07-28 | 0000950123-10-069041 | SEC ↗ |
| 2009-04-30 | 2009-08-27 | 0000950123-09-038702 | SEC ↗ |